First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2009-04-02 11:03:00Open Document File Size: 41,84 KBShare Result on FacebookCityRockville / Haven / /CompanyS-031 Bayer Pharmaceuticals Corporation / Bayer Pharmaceuticals Corporation / /EventFDA Phase / /FacilityNational Library of Medicine / /IndustryTermsupplemental new drug applications / drug product / supplemental applications / fluoroquinolone products / /MedicalConditionexaggerated sunburn / relative photosensitivity/phototoxicity / photosensitivity/phototoxicity / phototoxicity / erythema / severe blistering sunburns / severe sunburn / pain / pseudomembranous colitis / severe photosensitivity/phototoxicity / /MedicalTreatmentantibiotics / Drug therapy / /OrganizationFood and Drug Administration / Special Pathogen and Transplant Products Office / DEPARTMENT OF HEALTH / Division of Special Pathogen / Center for Drug Evaluation and Research Enclosure / /PersonRenata Albrecht / Kristen Miller / Janet Herrington / / /PositionPRECAUTIONS/General / Deputy Director / Regulatory Affairs / Director / physician / Regulatory Project Manager / M.D. Director / /Productmoxifloxacin hydrochloride / Avelox / NaCl injection / NDA / NDA Drug / Special / S-031 / S-038 / HFD-001 / /ProvinceOrStateMaryland / Connecticut / /URLhttp /SocialTag |